Publications 2021-11-15
Celea Therapeutics – Deupirfenidone (LYT-100)
Clinical Pharmacology in Drug Development: A randomized Phase 1 evaluation of deupirfenidone, a novel deuterium-containing drug candidate for interstitial lung disease and other inflammatory and fibrotic diseases